Clinical trials for pediatric MS should be prioritized to test only one or two of the most promising agents - Commentary

2016-11-01

Additional Metadata
Persistent URL	doi.org/10.1177/1352458516661240, hdl.handle.net/1765/94312
Journal	Multiple Sclerosis: clinical and laboratory research
Organisation	Department of Neurology
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Hintzen, R. (2016). Clinical trials for pediatric MS should be prioritized to test only one or two of the most promising agents - Commentary. Multiple Sclerosis: clinical and laboratory research, 22(13), 1653–1654. doi:10.1177/1352458516661240

Publication